Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 13,158 Shares

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 13,158 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $41.98, for a total transaction of $552,372.84. Following the transaction, the chief executive officer owned 18 shares in the company, valued at $755.64. This represents a 99.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.53, for a total value of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.32, for a total value of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total value of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.09, for a total value of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total transaction of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total transaction of $143,510.40.

Phibro Animal Health Price Performance

Shares of PAHC opened at $41.61 on Friday. The company’s 50-day moving average is $40.28 and its 200-day moving average is $37.41. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35. The firm has a market capitalization of $1.69 billion, a PE ratio of 25.07, a PEG ratio of 1.19 and a beta of 0.79. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $46.42.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. The business had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were paid a dividend of $0.12 per share. The ex-dividend date was Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. Phibro Animal Health’s dividend payout ratio (DPR) is 28.92%.

Institutional Investors Weigh In On Phibro Animal Health

A number of large investors have recently bought and sold shares of PAHC. Financial Management Professionals Inc. bought a new position in Phibro Animal Health in the 2nd quarter valued at about $32,000. Hughes Financial Services LLC acquired a new stake in shares of Phibro Animal Health during the 3rd quarter worth approximately $40,000. iSAM Funds UK Ltd bought a new position in Phibro Animal Health in the third quarter valued at approximately $61,000. EverSource Wealth Advisors LLC increased its stake in Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after acquiring an additional 2,685 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new position in Phibro Animal Health during the third quarter valued at approximately $96,000. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on PAHC. JPMorgan Chase & Co. upped their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Finally, Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.